Neurocrine Biosciences (NBIX) Asset Utilization Ratio (2011 - 2026)
Neurocrine Biosciences' Asset Utilization Ratio was 0.66 in Q2 2026, down 0.8% from 0.66 a year earlier but up 1.0% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
For FY2025, Asset Utilization Ratio at Neurocrine Biosciences came in at 0.69, up 1.4% from FY2024.
- Asset Utilization Ratio has now increased for four consecutive years.
- In earlier years, Asset Utilization Ratio was 0.68 in FY2024 (+0.6%), 0.67 in FY2023 (+0.2%), 0.67 in FY2022 (+12.6%) and 0.60 in FY2021 (-13.4%).
- Quarterly Asset Utilization Ratio has moved between 0.54 (Q3 2021) and 0.68 (Q1 2023) over five years.
- Compared with a year earlier, Asset Utilization Ratio has declined for three straight quarters, with growth averaging 2.5% over the last eight quarters.
- The best year-over-year quarter for Asset Utilization Ratio over five years was Q3 2022 (growth of 24.4%); the worst was Q3 2021 (a decline of 22.1%).
- Per Business Quant data, NBIX's Asset Utilization Ratio in the three quarters before Q2 2026 was 0.65 (Q1 2026), 0.64 (Q4 2025) and 0.66 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 0.49 |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 0.47 |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 0.52 |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | 0.44 |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 0.53 |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 0.40 |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | 0.58 |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 0.31 |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 0.47 |
| 10 | Neurocrine Biosciences | 14.06 Bn | 9.76 Bn | 935.80 Mn | 0.66 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.66 |
| Mar 31, 2026 | 0.65 |
| Dec 31, 2025 | 0.64 |
| Sep 30, 2025 | 0.66 |
| Jun 30, 2025 | 0.66 |
| Mar 31, 2025 | 0.65 |
| Dec 31, 2024 | 0.65 |
| Sep 30, 2024 | 0.66 |
| Jun 30, 2024 | 0.63 |
| Mar 31, 2024 | 0.59 |
| Dec 31, 2023 | 0.62 |
| Sep 30, 2023 | 0.65 |
| Jun 30, 2023 | 0.67 |
| Mar 31, 2023 | 0.68 |
| Dec 31, 2022 | 0.66 |
| Sep 30, 2022 | 0.67 |
| Jun 30, 2022 | 0.62 |
| Mar 31, 2022 | 0.57 |
| Dec 31, 2021 | 0.55 |
| Sep 30, 2021 | 0.54 |
API Access
Neurocrine Biosciences Asset Utilization Ratio API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=asset-utilization-ratio&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "asset-utilization-ratio", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=asset-utilization-ratio&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();